Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we evaluated rates of VTE recurrence and bleeding comp...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2021-04-01
|
Series: | TH Open |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728675 |
id |
doaj-2282bef639334a1e89e4e3281edb7a42 |
---|---|
record_format |
Article |
spelling |
doaj-2282bef639334a1e89e4e3281edb7a422021-05-04T22:57:57ZengGeorg Thieme Verlag KGTH Open2512-94652021-04-010502e143e15110.1055/s-0041-1728675Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC RegistryJan Beyer-Westendorf0Sandra Marten1Luise Tittl2Christiane Naue3Martin Bornhäuser4Thrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThe effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we evaluated rates of VTE recurrence and bleeding complications during apixaban treatment of VTE patients. For this analysis, we only included patients with acute VTE who started apixaban within 14 days after diagnosis and who were enrolled within these 14 days. Patient characteristics, treatment persistence, and clinical outcomes were assessed. Between August 1st, 2014 and October 31, 2018, 352 patients with apixaban treatment for acute VTE were enrolled. During treatment (median exposure 13.7 ± 9.8 months; median follow-up 21.7 ± 6.1 months) rates of recurrent VTE and International Society on Thrombosis and Haemostasis major bleeding were 1.3/100 pt.years (95% confidence interval or CI 0.4–3.0) and 1.5/100 pt.years (0.6–3.3), respectively. At 6 months. 68.6% of patients were still taking apixaban, 23.9% had a scheduled end of treatment, 6.3% were switched to other anticoagulants, and the remaining 2.3% had unplanned complete discontinuation of anticoagulation. Of the 188 patients stopping apixaban, 12 (6.4%) experienced a recurrent VTE (six pulmonary embolisms ± deep vein thrombosis, six deep vein thrombosis; mean time between stopping anticoagulation and VTE recurrence 5.2 ± 4.1 months [range 14–417 days]). Our findings suggest that, in daily care, apixaban demonstrated high effectiveness, safety, and persistence in the treatment of acute VTE with low rates of unplanned discontinuation.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728675anticoagulationbleedingpersistenceapixabanvenous thromboembolism |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jan Beyer-Westendorf Sandra Marten Luise Tittl Christiane Naue Martin Bornhäuser |
spellingShingle |
Jan Beyer-Westendorf Sandra Marten Luise Tittl Christiane Naue Martin Bornhäuser Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry TH Open anticoagulation bleeding persistence apixaban venous thromboembolism |
author_facet |
Jan Beyer-Westendorf Sandra Marten Luise Tittl Christiane Naue Martin Bornhäuser |
author_sort |
Jan Beyer-Westendorf |
title |
Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry |
title_short |
Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry |
title_full |
Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry |
title_fullStr |
Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry |
title_full_unstemmed |
Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry |
title_sort |
venous thromboembolism therapy with apixaban in daily care patients: results from the dresden noac registry |
publisher |
Georg Thieme Verlag KG |
series |
TH Open |
issn |
2512-9465 |
publishDate |
2021-04-01 |
description |
The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we evaluated rates of VTE recurrence and bleeding complications during apixaban treatment of VTE patients. For this analysis, we only included patients with acute VTE who started apixaban within 14 days after diagnosis and who were enrolled within these 14 days. Patient characteristics, treatment persistence, and clinical outcomes were assessed. Between August 1st, 2014 and October 31, 2018, 352 patients with apixaban treatment for acute VTE were enrolled. During treatment (median exposure 13.7 ± 9.8 months; median follow-up 21.7 ± 6.1 months) rates of recurrent VTE and International Society on Thrombosis and Haemostasis major bleeding were 1.3/100 pt.years (95% confidence interval or CI 0.4–3.0) and 1.5/100 pt.years (0.6–3.3), respectively. At 6 months. 68.6% of patients were still taking apixaban, 23.9% had a scheduled end of treatment, 6.3% were switched to other anticoagulants, and the remaining 2.3% had unplanned complete discontinuation of anticoagulation. Of the 188 patients stopping apixaban, 12 (6.4%) experienced a recurrent VTE (six pulmonary embolisms ± deep vein thrombosis, six deep vein thrombosis; mean time between stopping anticoagulation and VTE recurrence 5.2 ± 4.1 months [range 14–417 days]). Our findings suggest that, in daily care, apixaban demonstrated high effectiveness, safety, and persistence in the treatment of acute VTE with low rates of unplanned discontinuation. |
topic |
anticoagulation bleeding persistence apixaban venous thromboembolism |
url |
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728675 |
work_keys_str_mv |
AT janbeyerwestendorf venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry AT sandramarten venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry AT luisetittl venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry AT christianenaue venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry AT martinbornhauser venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry |
_version_ |
1721477180222865408 |